The currently marketed antibody-drug conjugates (ADC) destabilize microtubule assembly in cancer cells and initiate apoptosis in patients. However, few tumor antigens (TA) are expressed at high densities on cancer lesions, potentially minimizing the therapeutic index of current ADC regimens. The peptide/human leukocyte antigen (HLA) complex can be specifically targeted by therapeutic antibodies (designated T cell receptor [TCR]-like antibodies) and adequately distinguish malignant cells, but has not been the focus of ADC development. We analyzed the killing potential of TCR-like ADCs when cross-linked to the DNA alkylating compound duocarmycin. Our data comprise proof-of-principle results that TCR-like ADCs mediate potent tumor cytotoxicity, particularly under common scenarios of low TA/HLA density, and support their continued development alongside agents that disrupt DNA replication. Additionally, TCR-like antibody ligand binding appears to play an important role in ADC functionality and should be addressed during therapy development to avoid binding patterns that negate ADC killing efficacy.
Immunotherapeutic strategies such as unmodified antibodies have significantly advanced treatment options for individuals with cancer. Yet, to further improve the efficacy of this approach, engineered platforms such as antibody drug conjugates (ADCs) are under development. Current FDA-approved ADC designs incorporate tubulin inhibitors that abate cancer growth and mediate clinical protection for patients. However, successful ADC treatment typically requires high tumor antigen (TA) surface expression to bind/internalize ADC material, destabilize cytoskeletal networks, and suppress tumorigenesis. Unfortunately, few known TAs are localized on cancer cells at elevated densities, potentially minimizing the therapeutic index and widespread application of current ADC regimens. Our group sought to overcome this ADC limitation of TA expression by crosslinking the DNA alkylating compound duocarmycin with T cell receptor (TCR)-like antibodies, which specifically bind TA peptide/human leukocyte antigen (HLA) complexes analogous to a TCR. In select assays, a panel of TCR-like ADCs were capable of distinguishing human breast and colon cancer lines and promoting potent cell cytotoxicity even under common scenarios of low TA peptide/HLA densities. Additionally, TCR-like antibody TA peptide/HLA binding appeared to play an important role in ADC-mediated cytotoxicity, supporting the notion that spatial TA ligand interactions influence ADC function. Overall, our data highlight the proof-of-principle that TCR-like ADCs induce cancer cell death under physiologically-relevant TA expression profiles and support their translational development, particularly alongside agents that disrupt DNA replication.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.